18FDG-positron emission tomography in pancreatic cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Zimny, Michael ^a   Buell, Udalrich ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b NONE

Author keywords

FDG; Pancreatic carcinoma; Positron emission tomography

Indexed keywords

DEOXYGLUCOSE; GLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER CELL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; LYMPH NODE METASTASIS; MULTIPLE CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; PANCREAS TUMOR; REVIEW; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; PANCREATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032810668     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S28     Document Type: Conference Paper

References (57)

1. Nitecki SS, Sarr MG, Colby TV et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Annals of Surgery 1995; 221: 59-66
2. Lillemoe KD. Current management of pancreatic carcinoma. Annals of Surgery 1995; 221: 133-48
3. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. New Engl J Med 1992; 326: 455-65
4. Ruhmstadt B, Trede M, Chirurgische Therapie der Pankreaserkrankungen. Radiologe 1996; 36: 375-80
5. Phelps ME, Huang EJ, Hoffmann EJ et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (18F)2-fluoro-2-deoxy-D-glucose: validation of a method. Ann Neurol. 1979; 6: 371
6. Tillisch J, Brunken R, Marshall R et al. Reversibility of cardiac wall- motion abnormalities predicted by positron tomography. New Engl J Med 1986; 314: 884-8
7. Altehöfer C, Kaiser HJ, Dörr R et al. 18F deoxyglucose PET for assessment of viable myocardium in perfusion defects in 99mTc-MIBI SPECT: a comparative study in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 334-42
8. Lucignani G, Paolini G, Landoni C et al. Presurgical identification of hibernating myocardium by combined use of 99mTc-MIBI SPECT and 18F FDG PET in patients with cornary artery disease. Eur J Nucl Med 1992; 19: 874-81
9. Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-74
10. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14
11. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72: 2979-85
12. Binder C, Binder L, Marx D et al. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 1997; 17: 4299-304
13. Hawkins RA, Choi Y, Huang SC et al. Quantitating tumor glucose metabolism with FDG and PET (editorial). J Nucl Med 1992; 33: 339-44
14. Som P, Atkins HL, Bandoypadhyay D et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxictracer for rapid tumor detection. J Nucl Med 1980; 21: 670-5
15. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in braintumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987; 22):360-71
16. Gupta NC, Frank AR, Dewan NA et al. Solitary pulmonary nodules: Detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992; 184: 441-4
17. Steinert HC, Hauser M, Allemann F et al. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-6
18. Thill R, Neuerburg J, Fabry U et al. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma]. Nuklearmedizin 1997; 36: 234-9
19. Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-8
20. Steinert HC, Huch Boni RA, Buck A et al. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-9
21. Laubenbacher C, Saumweber D, Wagner-Manslau C et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36: 1747-57
22. Anzai Y, Carroll WR, Quint DJ et al. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200: 135-41
23. Lapela M, Grenman R, Kurki T et al. Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1995; 197: 205-11
24. Ogunbiyi OA, Flanagan FL, Dehdashti F et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann.Surg.Oncol. 1997; 4: 613-20
25. Stumpe KDM, Urbinelli M, Steinert HC et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8
26. Rinne D, Baum RP, Hoer G et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 1998; 82: 1664-71
27. Bares R, Klever P, Hellwig D et al. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun. 1993; 14: 596-601
28. Higashi T, Tamaki N, Honda T et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-44
29. Reske SN, Grillenberger KG, Glatting G et al. Overexpression of glucose transporter I and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-8
30. Higashi T, Tamaki N, Torizuka T et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727-35
31. Bares R, Klever P, Hauptmann S et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86
32. Inokama T, Tamaki N, Torizuka T et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluordeoxyglucose: Comparison with CT and US. Radiology 1995; 195:345-52
33. Inokama T, Tamaki N, Torizuka T et al. Value of fluorine-18-fluorodeoxyglucose and thallium in the detection of pancreatic cancer. J Nucl Med 1995; 36: 229-35.
34. Friess H, Langhans J, Ebert M et al. Diagnosis of pancreatic cancer by 2[18-F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36: 771-7
35. Kato T, Hiroshi F, Ito K et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995; 22: 32-9
36. Stollfuss JC, Glatting G, Friess H et al. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195: 339-44.
37. Ho CL, Dehdashti F, Griffeth LK et al. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomography 1996; 20: 363-9
38. Zimny M, Bares R, Fass J et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases. Eur J Nucl Med 1997; 24: 678-82
39. Diederichs CG, Staib L, Glatting G et al. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998; 39: 1030-3
40. Syrota A, Duquesnoy N, Paraf A et al. The role of positron emission tomography in the detection of pancreatic disease. Radiology 1982; 143:249-53
41. Shreve PD, Gross MD. Imaging of the pancreas and related disease with PET carbon-11-acetate. J Nucl Med 1997; 38: 1305-10
42. Strauss LG, Conti PS. The applications of PET in clinical oncology J Nucl Med 1991; 32: 623-48
43. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination. Brain Res Rev 1982;4 : 237-74
44. Patlak Cs, Blasberg RG, Fenstermacher JD. Graphic evaluation of blood to brain transfer constants from multiple time uptake data. J cereb Blood Flow Metabolism 1983; 3: 1-7
45. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25: 259-64
46. Nitzsche E, Hoegerle S, Krause T et al. Noninvasive differentiation between benign and malignant focal lesions of the pancreas: Are results of a kinetic analysis superior to those derived by SUV analysis. Eur J Nucl Med 1998; 25: 942 (abstract)
47. Fröhlich A, Diederichs CG, Staib L et al. FDG-PET in the detection of pancreatic liver metastases J Nucl Med 1997; 38: 145P (abstract)
48. Müller MF, Meyenberger C, Bertschinger P et al. Pancreatic tumors: evaluation with endoscopic US, CT, and MR Imaging. Radiology 1994; 190: 745-51
49. Megibow A, Zhou X, Rotterdam H et al. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of Resectability - Report of the radiology diagnostic oncology group Radiology 1995; 195: 327-32.
50. Zeman RK, Cooper C, Zeiberg AS et al. TNM staging of pancreatic carcinoma using helical CT. AJR 1997; 169: 459-64
51. Bares R, Dohmen BM, Cremerius U et al. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma] Radiologe 1996; 36: 435-40
52. Nakata B, Chung YS, Nishimura S et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997; 79:695-9
53. Zimny M, Fass J, Bares R et al. F-18-FDG-PET and the prognosis in pancreatic carcinoma. J Nucl Med 1998; 39: 81P (abstract)
54. Benyounes H, Smith FW, Campbell C et al. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Nucl Med Comm 1995; 16: 575-80
55. Dohmen BM, Bares R, Sabri O et al. Image-fusion of abdominal PET-MRI studies by anatomically weighted external markers: methodological aspects and experience in routine use. Eur J Nucl Med 1995; 22: 789 (abstract)
56. Bares R, Gehl HB, Kaiser HJ et al. Magnetic-resonance-imaging (MRI) and positron-emission-tomography (PET) using fluorine-18 labeled deoxyglucose (FDG) for detection of pancreatic cancer: Comparison and image merging. Eur J Nucl Med 1993; 20: 977 (abstract)
57. Kaiser HJ, Bares R, Wagenknecht G et al. Method for exact image correlation and merging of magnetic resonance images (MRI) and positron emission tomography (PET) for the detection of pancreatic cancer. Eur J Nucl Med 1993; 20: 991 (abstract)